Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.

MLA

Pett, Sarah Lilian, et al. “Maraviroc, as a Switch Option, in HIV-1-Infected Individuals With Stable, Well-Controlled HIV Replication and R5-Tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-Boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 63, no. 1, July 2016, pp. 122–32. EBSCOhost, https://doi.org/10.1093/cid/ciw207.

APA

Pett, S. L., Amin, J., Horban, A., Andrade-Villanueva, J., Losso, M., Porteiro, N., Sierra Madero, J., Belloso, W., Tu, E., Silk, D., Kelleher, A., Harrigan, R., Clark, A., Sugiura, W., Wolff, M., Gill, J., Gatell, J., Fisher, M., Clarke, A., … Emery, S. (2016). Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 63(1), 122–132. https://doi.org/10.1093/cid/ciw207

Chicago

Pett, Sarah Lilian, Janaki Amin, Andrejz Horban, Jaime Andrade-Villanueva, Marcelo Losso, Norma Porteiro, Juan Sierra Madero, et al. 2016. “Maraviroc, as a Switch Option, in HIV-1-Infected Individuals With Stable, Well-Controlled HIV Replication and R5-Tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-Boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 63 (1): 122–32. doi:10.1093/cid/ciw207.